| Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study of ELEVIDYS (delandistrogene moxeparvovec-rokl) for the treatment of Duchenne muscular dystrophy. Treatment with ELEVIDYS in the ENDEAVOR participants in cohort 6 who were 2 years old at the time of treatment (n=6), demonstrated mean expression of 93. |
businesswire.com |
2025-05-16 13:01:00 |
Czytaj oryginał (ang.) |
| Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore |
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound. |
marketbeat.com |
2025-05-14 12:30:32 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo. |
businesswire.com |
2025-05-13 13:25:00 |
Czytaj oryginał (ang.) |
| 2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying |
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when trading near its 52-week low. |
fool.com |
2025-05-13 08:14:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 14:15:00 |
Czytaj oryginał (ang.) |
| Top 3 Health Care Stocks That Are Preparing To Pump This Quarter |
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. |
benzinga.com |
2025-05-09 11:16:56 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics to Present at the BofA Securities Health Care Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities Health Care Conference at the Encore Hotel in Las Vegas, Nev. on Wednesday, May 14, 2025 at 8:40 a.m. P.T./11:40 a.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/eve. |
businesswire.com |
2025-05-08 20:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating |
Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Buy" to "Hold" due to uncertainty around sales of DMD drug ELEVIDYS and patient death investigation still underway. Financial risks include potential need for additional funds, possibly diluting shareholders, despite Q1 2025 revenue increase of 70% YoY. |
seekingalpha.com |
2025-05-07 18:14:41 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up |
Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents. |
benzinga.com |
2025-05-07 17:07:25 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade |
Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show mixed SRPT performance: revenue beat expectations, but EPS missed, and cash reserves dropped significantly. ELEVIDYS uptake slowed by safety concerns and a temporary clinical trial hold, causing reduced revenue guidance and cautious market adoption. |
seekingalpha.com |
2025-05-07 16:14:34 |
Czytaj oryginał (ang.) |
| SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut |
SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance. |
zacks.com |
2025-05-07 13:35:43 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results |
Sarepta Therapeutics, Inc. SRPT posted a loss for the first quarter on Tuesday. |
benzinga.com |
2025-05-07 13:28:40 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday. |
benzinga.com |
2025-05-07 12:10:18 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT |
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript |
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, IR Doug Ingram - President and CEO Dallan Murray - EVP, CCO Louise Rodino-Klapac - EVP, Head of R&D, CSO Ian Estepan - EVP, CFO Conference Call Participants Tazeen Ahmad - Bank of America Securities Ritu Baral - TD Cowen Louise Chen - Scotiabank Andrew Tsai - Jefferies Eliana Merle - UBS Brian Abrahams - RBC Capital Markets Debjit - Guggenheim Securities Salveen Richter - Goldman Sachs Brian Skorney - Baird Michael Ulz - Morgan Stanley Gil Blum - Needham & Company Joe Schwartz - Leerink Partners Yanan Zhu - Wells Fargo Kostas Biliouris - BMO Capital Markets Anupam Rama - JPMorgan Biren Amin - Piper Sandler David Hoang - Deutsche Bank Rick Miller - Cantor Fitzgerald Andreas Argyrides - Oppenheimer & Co. Gena Wang - Barclays Operator Good afternoon, and welcome to the Sarepta Therapeutics First Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded. |
seekingalpha.com |
2025-05-07 02:41:43 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-06 23:00:32 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates |
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $3.42 per share versus the Zacks Consensus Estimate of $0.35. This compares to earnings of $0.73 per share a year ago. |
zacks.com |
2025-05-06 22:40:47 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT |
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-06 20:13:00 |
Czytaj oryginał (ang.) |
| Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales |
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline. |
zacks.com |
2025-02-27 11:45:30 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript |
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz - Leerink Partners Gil Blum - Needham & Company Ritu Baral - TD Cowen Brian Skorney - Baird David Hoang - Deutsche Bank Ry Forseth - Guggenheim Securities Priyanka Grover - JPMorgan Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore Sami Corwin - William Blair Leo Watson - Mizuho Operator Good afternoon. And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-02-27 01:48:41 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates |
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago. |
zacks.com |
2025-02-26 20:25:29 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2024. “2024 performance represented the fruition of our multi-year strategy to become a self-sustaining profitable biotech dedicated to improving the lives of patients with rare genetic disease. After obtaining a broad label for our gene therapy ELEVIDYS covering the vast majority of Duchenn. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-02-26 13:01:30 |
Czytaj oryginał (ang.) |
| Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-02-17 12:35:18 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent. |
businesswire.com |
2025-02-14 10:30:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 26, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website a. |
businesswire.com |
2025-02-12 10:30:00 |
Czytaj oryginał (ang.) |
| Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics |
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli. |
businesswire.com |
2025-02-10 10:30:00 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks to Buy Hand Over Fist in February |
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring. |
fool.com |
2025-02-09 11:10:00 |
Czytaj oryginał (ang.) |
| Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates? |
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings. |
zacks.com |
2025-02-03 10:45:30 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. Crossover-treated patients, those who received a placebo in Part 1 and. |
businesswire.com |
2025-01-27 03:00:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely |
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals. |
seekingalpha.com |
2025-01-16 15:23:25 |
Czytaj oryginał (ang.) |
| Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan |
Sarepta + Arrowhead +0.18 (+0.97%) |
https://thefly.com |
2025-01-13 17:00:25 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. Financial Update* (preliminary and unaudited): Total net product revenue of $638.2 million for the fourth quarter and $1.79 bi. |
businesswire.com |
2025-01-13 14:25:00 |
Czytaj oryginał (ang.) |
| Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference |
LUND, Sweden , Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. |
prnewswire.com |
2025-01-07 13:19:00 |
Czytaj oryginał (ang.) |
| SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell? |
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential. |
zacks.com |
2025-01-06 10:51:18 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T. The presentation will be webcast live under the Events & Presen. |
businesswire.com |
2025-01-06 10:30:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq List. |
businesswire.com |
2024-12-31 18:10:00 |
Czytaj oryginał (ang.) |
| Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku |
Japanese drugmaker Nippon Shinyaku infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday. |
reuters.com |
2024-12-20 18:45:37 |
Czytaj oryginał (ang.) |
| 4 Biotech Stocks Most Wall Street Analysts Are Bullish About |
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals. |
zacks.com |
2024-12-19 16:25:23 |
Czytaj oryginał (ang.) |
| SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder |
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management. |
zacks.com |
2024-12-19 11:45:37 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is t. |
businesswire.com |
2024-12-18 10:30:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 |
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025. |
zacks.com |
2024-12-17 12:01:04 |
Czytaj oryginał (ang.) |
| FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe |
New Food and Drug Administration (FDA) guidance on accelerated approval for drugs targeting “serious conditions” appears to be a positive move for rare diseases, analysts at Jefferies believe. The FDA earlier this month published the draft guidance on its policies and procedures for the accelerated approval (AA) pathway for drugs for serious conditions that fulfil an unmet medical need. |
proactiveinvestors.com |
2024-12-13 13:20:08 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? |
The consensus price target hints at a 48% upside potential for Sarepta Therapeutics (SRPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-12-13 12:56:15 |
Czytaj oryginał (ang.) |
| Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? |
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-09 08:48:40 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Lis. |
businesswire.com |
2024-11-29 18:10:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock? |
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD. |
zacks.com |
2024-11-29 17:01:17 |
Czytaj oryginał (ang.) |
| SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies |
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders. |
zacks.com |
2024-11-27 14:35:26 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet |
The mean of analysts' price targets for Sarepta Therapeutics (SRPT) points to a 42.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-27 13:00:51 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S. |
businesswire.com |
2024-11-26 09:00:00 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step |
Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025 and a potential BLA filing by mid-2025. Despite strong revenues, Sarepta may need to raise additional funds within the next 12 months to support ongoing operations and development programs from its pipeline. |
seekingalpha.com |
2024-11-08 17:02:50 |
Czytaj oryginał (ang.) |
| SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program |
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program. |
zacks.com |
2024-11-07 12:20:30 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript |
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Dallan Murray - Executive Vice President and Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Gena Wang - Barclays Andrew Tsai - Jefferies Anupam Rama - JPMorgan Danielle Brill - Raymond James Eliana Merle - UBS Gil Blum - Needham & Company Ritu Baral - TD Cowen Joseph Schwartz - Leerink Partners Kostas Biliouris - BMO Capital Markets Brian Skorney - Baird Kristen Kluska - Cantor Fitzgerald Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore ISI Leo Watson - Mizuho Sami Corwin - William Blair Operator Good day and welcome to the Sarepta Therapeutics Third Quarter 2024 Financial Results Conference Call. After the speakers' presentation, there will be a question-and-answer session. |
seekingalpha.com |
2024-11-07 04:10:29 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics (SRPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-11-06 21:36:28 |
Czytaj oryginał (ang.) |
| Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 6, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2024 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sar. |
businesswire.com |
2024-10-23 12:30:00 |
Czytaj oryginał (ang.) |
| 2 High-Flying Growth Stocks With Massive Upside Potential |
These innovative drugmakers have potential catalysts ahead. |
fool.com |
2024-10-17 13:53:00 |
Czytaj oryginał (ang.) |